Veru Inc., a biopharmaceutical company, will present its research on obesity and weight loss drug development at the 2026 Obesity & Weight Loss Drug Development Summit in Boston. The company focuses on combining its drug enobosarm, a selective androgen receptor modulator, with GLP-1 receptor agonists to improve fat loss while preserving muscle mass in older patients. Veru is currently conducting a Phase 2b clinical trial called PLATEAU to evaluate this combination's effectiveness and plans to share interim results in early 2027. This research aims to enhance weight loss treatments by addressing muscle loss and improving physical function in obese elderly patients.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
